 | SGLT2i for type 2 diabetes management in patients diagnosed with CKD SGLT2i for type 2 diabetes management in people at risk of, or diagnosed
with, CVD SGLT2i for hyperglycaemia management in patients with type 2 diabetes Type 2 diabetes – rational use of pharmacotherapy Type 2 diabetes – monitoring and technology Diabetes – prevention |
| CVD – holistic care CVD – pharmacological management CVD – risk and primary prevention Matters of the heart: identifying and managing cardiovascular disease risk |
 | The Kidney Health Check: who needs one and how often should they be done? Cardiovascular risk assessment in chronic kidney disease Controversies in CVD management in people with CKD |
 | Could my patient with anaemia have cancer? Abnormal test results and cancer risk: Prostate-Specific Antigen (PSA) Abnormal test results and cancer risk: Thrombocytosis |
 | QI activity measurement and reporting Elements of quality improvement including small group clinical audit activities Frameworks for developing and implementing QI Key elements of quality improvement and the roles and responsibilities to make it work |